Articles
-
Jan 14, 2025 |
bmccancer.biomedcentral.com | Lijuan He |Haiyuan Li |Ben Liu |Yunpeng Wang |Bo Xu |Jike Hu | +6 more
This study applied a prospective, observational (non-randomized) design, recruiting patients receiving anticancer agents from March 2021 to August 2021. This work didn’t interfere with clinical decision-making or risk beyond conventional treatment, enrolling and following only patients prescribed fosaprepitant. No identifiable information will be included in the recorded data to protect the privacy of the subjects.
-
Apr 6, 2024 |
mdpi.com | Jinhui Wu |Yibo Wang |Lijuan He |Lijuan Wang
All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →